Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Recruiting 3Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Sarcoma 1

Conditions

Breast Neoplasms 31Neoplasms 8Endometrial Neoplasms 6Neoplasm Metastasis 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Head and Neck Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Meningioma 3Glioblastoma 3Sarcoma 2Pancreatic Neoplasms 2Oligodendroglioma 2Lymphoma, Non-Hodgkin 2Carcinoma, Non-Small-Cell Lung 2Urologic Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Retinoblastoma 1Recurrence 1Pathologic Complete Response 1Osteosarcoma 1Neoplasms, Squamous Cell 1Neoplasm, Residual 1Multiple Myeloma 1

Interventions

Carboplatin 79Paclitaxel 64pembrolizumab 63Cyclophosphamide 47Capecitabine 34Doxorubicin 31Taxes 28130-nm albumin-bound paclitaxel 28Albumin-Bound Paclitaxel 27Gemcitabine 20atezolizumab 18Epirubicin 18Cisplatin 18Bevacizumab 18olaparib 17sacituzumab govitecan 15Docetaxel 15eribulin 14toripalimab 13durvalumab 13camrelizumab 13Drug Therapy 12apatinib 9Trastuzumab 9Radiotherapy 9Specimen Handling 8Magnetic Resonance Spectroscopy 8Biopsy 8tislelizumab 7talazoparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Triple Negative Breast Neoplasms × abemaciclib × Clear all
NCT07340541 2026-05-20

EVOLVE-BDT

UNC Lineberger Comprehensive Cancer Center

Phase 2 Recruiting
700 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06365788 2026-04-01

ABBICAR

Universitaire Ziekenhuizen KU Leuven

Phase 2 Recruiting
53 enrolled
Breast

Bulbo-Spinal Atrophy, X-Linked, Triple Negative Breast Neoplasms

NCT03979508 2025-11-12

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Mayo Clinic

Phase 2 Terminated
26 enrolled
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Fibrocystic Breast Disease, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡